The Target: BP program helped us to standardize our procedure for blood pressure determination across the clinic as a whole, thus leading to improved patient outcomes and quality of care delivery”said Thomas Mihelich, M.D., Chief Quality Officer at Utica Park Clinic in Tulsa, Oklahoma, one of 340 clinics receiving Gold level recognition this year. Of the 103 million Americans with high blood pressure, less than half of them have it controlled to a healthy level. Through the Target: BP program, healthcare providers have access to tools and resources to not only help them remain mindful of blood pressure management but help more of their patients become involved with their care and health goals in order to get their blood pressure under control.Related StoriesHealthy blood vessels could help stave off cognitive declineDon’t ignore diastolic blood pressure values, say researchersScientists turn type A blood into universal type O, potentially doubling blood transfusion stocks“A driving force behind Target: BP’s goal of improving cardiovascular health is the physician and patient partnership,” said AHA President Ivor Benjamin, M.D., FAHA. “No single risk factor has more impact on the nation’s death rates from cardiovascular disease than high blood pressure. We are pleased to see more and more practices prioritize blood pressure control and collaborate with their patients to achieve the program’s goal of reducing heart disease and strokes in their communities.”Experts agree that high blood pressure can often be managed effectively when patients work with their physician to create and follow a treatment plan.“Although we have the tools to effectively treat high blood pressure, many patients face a variety of barriers making it difficult to successfully manage the condition. Target: BP is meant to facilitate ways around those barriers,” said AMA President Barbara L. McAneny, M.D. “We applaud the physicians who are already working hard to control their patients’ blood pressure. And, because we know that improving control rates by just a few percentage points can lead to tens of thousands of additional hypertensive patients with controlled blood pressure, we will continue to urge more physician practices, health systems and patients to join this effort to prioritize blood pressure control. By increasing the national blood pressure control rate, we will be able to save many more lives and improve health outcomes for patients throughout the nation.”More than 1,650 physician practices and health systems nationwide have joined Target: BP™ since 2015, sharing a common goal to reduce the number of adult patients with uncontrolled blood pressure and improve health outcomes associated with heart disease. Launched in 2017, the Target: BP Recognition Program is an extension of Target: BP™. More information about Target: BP and a full list of this year’s recognized participants can be found at TargetBP.org. Source:https://www.ama-assn.org/ Oct 19 2018American Heart Association and American Medical Association award physician practices and health systems with Target: BP™ Recognition Program designation for their commitment to prioritize blood pressure control within the communities they serve The American Heart Association (AHA) and the American Medical Association (AMA) today recognized 802 physician practices and health systems from across the country for their commitment to reducing the number of Americans who have heart attacks and strokes each year. As part of the annual Target: BP Recognition Program, run jointly by the two associations since 2017, these practices are being recognized for their commitment to helping more patients improve blood pressure control.More than 8.7 million people with high blood pressure are represented by this year’s 802 program participants. The highest level of achievement in the program is to reach a control rate of 70 percent or more, signifying Gold status. According to this year’s Target: BP data, nearly half of Target: BP Recognition Program participants reached Gold status—with these health care organizations achieving on average 77 percent of their hypertensive patients’ blood pressure controlled. Data for the program is based on high blood pressure control being defined as less than 140/90 mmHg.
Reviewed by Alina Shrourou, B.Sc. (Editor)Nov 30 2018Bottom Line: Patients from the poorest neighborhoods who had cardiac arrest had longer total ambulance times than those from the wealthiest neighborhoods.Why The Research Is Interesting: Emergency medical services (EMS) provide critical care before patients reach the hospital and differences in ambulance times may contribute to disparities in patient outcomes.Related StoriesMore patients may suffer cardiac arrests than previously estimatedStudy analyzes high capacity of A. baumannii to persist on various surfacesHome-based support network helps stroke patients adjust after hospital dischargeWhat and When: National data from 46 states on 63,600 patients who had cardiac arrest and didn’t die on scene and were transported to a hospitalWhat (Study Measures and Outcomes): Four time measures were examined (response time, on-scene time, transport time and total EMS time) and compared with EMS response time benchmarks for responding to cardiac arrest calls.How (Study Design): This was an observational study. Researchers weren’t intervening for purposes of the study and cannot control all the natural differences that could explain the study findings.Authors: Renee Y. Hsia, M.D., M.Sc., University of California, San Francisco, and coauthorsStudy Limitations: The registry analyzed for this study wasn’t of individual patients so multiple reports associated with the same patient exist; other explanations beyond the variables assessed in this study may have contributed to time disparities; and the findings may not be generalized to other types of time-sensitive EMS calls. Source:https://media.jamanetwork.com/news-item/do-lower-income-neighborhoods-experience-longer-ambulance-times/ read more
Source:http://web.era-edta.org/ Reviewed by Alina Shrourou, B.Sc. (Editor)Apr 10 2019The link between brain dysfunction and advanced kidney disease was first noted in 1930, so it is not a new finding. Experts spoke of ‘dialysis dementia’ or ‘uremic encephalopathy’. What is new, however, is the finding that mild cognitive impairment (MCI) may already be present in earlier stages of CKD, affecting approximately one in two CKD patients (prevalence varies in studies between 30% and 60%). In contrast to ‘normal’ dementia, CKD-related MCI is not age-related, meaning the cognitive impairment exceeds that expected of the normal aging process. It usually worsens with declining glomerular filtration rate (GFR) of patients – the lower the GFR, the higher the risk of being affected by cognitive impairments.Related StoriesLow dose of endotoxin could have protective effect on men at risk of acute kidney injuryChronic kidney disease patients are excluded from clinical trialsIndigestion remedy improves survival in people with late-stage CKDThe pathogenesis appears complex, involving a variety of factors besides vascular disease – the most frequent trigger for ‘standard’ dementia in elderly people. Dialysis does not help or stop the process of cognitive decline, thus experts believe that factors which are not corrected completely by dialysis, for example the clearance of middle molecules, uncontrolled secondary hyperparathyroidism and anemia, may further the process of cognitive impairment.’One interesting finding, though, is that kidney transplantation appears to slow cognitive decline’, explains Professor Giovambattista Capasso, one of the authors of a review recently published in NDT. ‘This highlights the importance of transplantation, because we have no other intervention strategies once cognitive decline has been diagnosed in CKD patients.’The paucity of intervention strategies is the reason why there is no routine screening for MCI in CKD patients. The authors of the review emphasize that cognitive decline is one of many manifestations of brain damage that clearly accompany the decline of kidney function. Other manifestations include sleep disorders and depression, both of which are also common in CKD patients. ‘Chronic kidney disease is an illness that obviously affects the body and the brain. The latter has been neglected by research, but new tools in neuroscience, such as tractography or two-photon microscopy hold out the promise of gaining further insights in the pathogenesis of MCI so that we might identify therapy targets and be able to treat it one day’, explains Professor Capasso.’Until then, we have to be aware that CKD is a severe disease which affects not only the kidneys, but also other organs systems and the brain – even in early stages. This is why we should strengthen CKD prevention strategies and raise awareness for this illness that is much more severe than most people think’, adds Professor Carmine Zoccali, president of the ERA-EDTA. read more
Reviewed by James Ives, M.Psych. (Editor)Apr 17 2019The commonly used diabetes drug metformin could reverse the harmful thickening of heart muscle that leads to cardiovascular disease, according to a study at the University of Dundee.Scientists led by Professor Chim Lang, Head of the Division of Molecular and Clinical Medicine at Dundee, discovered that metformin has the potential to be repurposed as a heart disease treatment in non-diabetic patients.The MET-REMODEL Trial, published today in the prestigious European Heart Journal, showed that metformin, used to treat type 2 diabetes safely for the last six decades, reduced left ventricular hypertrophy (LVH) in patients with prediabetes and pre-existing heart disease. LVH is the thickening of the muscle wall in the heart’s left pumping chamber and is a serious risk factor for future heart attack, stroke and heart failure.LVH is often a silent symptom and most people do not know they have it prior to experiencing a heart attack or stroke. Large studies have previously shown that patients with LVH are at higher risk of adverse cardiovascular events and reducing LVH can substantially reduce mortality rates.Professor Lang said, “Cardiovascular diseases are the leading cause of global mortality. We have previously shown that metformin can have beneficial effects in patients with cardiovascular diseases. But this is the first time anyone has looked specifically at the effects of metformin on LVH in nondiabetic patients with coronary artery disease in a clinical trial.”The study involved treating prediabetic people with coronary artery disease with metformin or a placebo over a period of 12 months to see how the drug affected the heart muscle wall, using state-of-the-art MRI technology.”The major causes of LVH are high blood pressure, obesity and insulin resistance, which are also thought to be key contributors of coronary artery disease. The dangerous thickening of the left ventricle was reduced by twice as much in those taking metformin compared to the placebo.Related StoriesHeart disease is still the number 1 killer in Australia, according the latest figuresTeam approach to care increases likelihood of surviving refractory cardiogenic shockRNA-binding protein SRSF3 appears to be key factor for proper heart contraction, survival”We also found that metformin reduced blood pressure, oxidative stress and lost body weight – an average of 3.6 kg, compared to no changes in the placebo group. If the findings from this study are substantiated in a larger-scale study, metformin could offer hope for millions of patients across the globe.”The MET-REMODEL trial, funded by the British Heart Foundation (BHF), is the first clinical trial in the world to show that metformin could reverse harmful thickening heart muscle wall in a clinical trial. Repurposing cheap and readily available drugs, such as metformin, to treat other health conditions could potentially save the NHS billions of pounds every year.Mohapradeep Mohan, lead author and principal investigator of the MET-REMODEL trial, said blood pressure medications were the standard treatment modalities for LVH but that this approach was not particularly effective as LVH can also be present in patients who have well-controlled blood pressure. This highlighted the need for new treatment strategies in these patients.”In this context, we need non-blood pressure medication and we had good reason to suppose that metformin should help to reduce thickening of heart muscle wall,” he said.”The findings from our study reinforce the notion that metformin has the potential to improve cardiovascular health, offering the possibility of improving life expectancy of patients. From the standpoint of clinical practice, this drug is already approved and well tolerated with minimal side effects.”If our findings are backed up by bigger studies, using metformin to target LVH presents a novel treatment option and unique opportunity for a quicker translation to the clinic. We are thankful to BHF for funding this study and extremely grateful to all the participants of this study.” Source:https://www.dundee.ac.uk/ read more
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only. Swiss food giant Nestle announced Monday it will pay $7.15 billion in cash for the rights to market Starbucks products around the world, outside of the company’s coffee shops. Starbucks commits $10M for greener coffee cup Brewing up a ‘global coffee alliance’ The agreement gives Nestle, which owns the Nescafe and Nespresso brands, a strong platform for continued growth in North America, the company said in a statement.Nestle is focusing on coffee as a main growth area and has already made some acquisitions in the sector.The Starbucks business covered by the deal currently generates around $2 billion sales annually and includes coffee beans and ground coffee that Nestle will be selling in supermarkets around the world.”This transaction is a significant step for our coffee business, Nestle’s largest high-growth category,” said Nestle CEO Mark Schneider in a statement.”Both companies have true passion for outstanding coffee and are proud to be recognised as global leaders for their responsible and sustainable coffee sourcing,” he said.The deal does not include any of Starbucks’ coffee shops and cafes.Around 500 Starbucks staff will join Nestle, the company said, but the operations would continue to be located in Seattle.Both companies would collaborate on “innovation and go-to-market strategies”, it said.Starbucks president and CEO Kevin Johnson hailed the deal as “historic” and said it would create a “global coffee alliance”. Nestle, which has been under intense shareholder pressure to improve its profitability, has begun to reposition itself since Schneider took over at the start of last year.The former head of German healthcare group Fresenius has pushed for the food giant to focus in on a few areas, like bottled water, infant nutrition and pet care, with coffee a top priority.’Unexpected transaction’While Nestle’s Nespresso and other coffee products are omnipresent in Europe, they have had a harder time catching on in the United States.Over the past 15 months, the company has clearly set its sights on high-end coffee brands in North America. It snapped up a majority share in California-based Blue Bottle Coffee last September, and two months later bought Texas company Chameleon Cold Brew.At the same time, Nestle has been selling off parts of its confectionary business, handing over its US candy business earlier this year to Italy’s Ferrero for nearly $3.0 billion.Analysts hailed Monday’s deal.”Nestle has once again surprised the market with an unexpected transaction,” Jean-Philippe Bertschy of Vontobel said in a research note.He said that “coffee is one of the key growth pillars in the CEO’s strategy, (and) allows Nestle to gain scale in the US, a weak spot so far.”He acknowledged that “the price might appear expensive, but given the returns, the deal could exceed the cost of capital within three to four years”. The transaction, which needs approval from regulators, should be finalised by the end of 2018, Nestle said, adding that the deal should start making a positive contribution to its earnings per share and its growth targets starting next year.The company saw its shares swell 0.6 percent in mid-morning trading at 76.84 Swiss francs a piece, as the Swiss stock exchange’s main SMI index was up just 0.15 percent.Starbucks, meanwhile, said it will use the cash to accelerate share buybacks. The Seattle-based company said it now expected to return some $20 billion to shareholders through buybacks and dividends by 2020. © 2018 AFP Explore further Citation: Nestle pays $7.15 billion to sell Starbucks products (2018, May 7) retrieved 18 July 2019 from https://phys.org/news/2018-05-nestle-billion-starbucks-products.html read more
Press Trust of India New DelhiJuly 12, 2019UPDATED: July 12, 2019 16:25 IST Shashi Tharoor with Rahul Gandhi.Parliamentarians who have a slightly different relationship with their constituencies and are less frequently seen there have a rough time, according to Congress MP Shashi Tharoor.Speaking at a conclave in Delhi on Thursday, Tharoor, who has been elected to the Lok Sabha from Thiruvananthapuram in Kerala thrice in a row since 2009, said he believes he has done his job properly and that is the reason why people have reposed faith in him.After the recent Lok Sabha elections results, critics attributed the loss of Congress leader Rahul Gandhi from his family’s pocket borough Amethi to his disconnect with the voters of that constituency.Tharoor, though, pointed towards only MPs from the BJP and those from northern India in support of his contention.”MPs, particularly those from the north, who have a slightly different relationship with their constituencies and are less frequently seen there have a rough time,” he said.”They are the ones who can perhaps win only in Narendra Modi’s name and they do, like this time. But for most of us what differentiates us is precisely the work we do in our constituencies,” he said.He said people re-elected him as they believe that he has done his job properly.”People have seen me, seen me attending to their needs and that’s why they have trusted and voted for me.”Tharoor was speaking on the topic “Clients and Constituents: Political Responsiveness in Patronage Democracies” which is also the title of a book by academician Jennifer Bussell.The third edition of the South Asia Conclave organised by Oxford University Press witnessed researchers, policymakers, bureaucrats, academicians, and journalists from debating contemporary ideas that define modern South Asia.The conclave closely examined the key issues impacting the region, such as political challenges related to ethnic and religious diversity, identity politics, ethnic violence, terrorism, separatism, governance, economic growth, gender consciousness, national security, changes in culture and social structure as well as the significance of diaspora.Also Read | Shashi Tharoor uses cricket analogy to criticise Union BudgetAlso Watch | Congress altered ground reality while in power, Shashi Tharoor hits back at PM ModiFor the latest World Cup news, live scores and fixtures for World Cup 2019, log on to indiatoday.in/sports. Like us on Facebook or follow us on Twitter for World Cup news, scores and updates.Get real-time alerts and all the news on your phone with the all-new India Today app. Download from Post your comment Do You Like This Story? Awesome! Now share the story Too bad. Tell us what you didn’t like in the comments Posted bySanchari Chatterjee Next MPs not frequenting their constituencies have rough time: Shashi TharoorCongress MP Shashi Tharoor has said MPs who do not visit their constituencies often have a tough time.advertisement read more